2014
DOI: 10.1155/2014/939713
|View full text |Cite
|
Sign up to set email alerts
|

Daytime Sleepiness in Parkinson's Disease: Perception, Influence of Drugs, and Mood Disorder

Abstract: Parkinson's disease (PD) is associated with sleep complaints as excessive daytime sleepiness (EDS) and several factors have been implicated in the genesis of these complaints. Objective. To correlate the subjective perception of EDS with variables as the severity of the motor symptoms, medications, and the presence of depressive symptoms. Materials and Methods. A cross-sectional study, using specific scales as Epworth sleepiness scale (ESS), Beck depression inventory (iBeck) and Hoehn and Yahr (HY), in 42 pati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
12
0
2

Year Published

2014
2014
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 19 publications
(14 citation statements)
references
References 28 publications
(39 reference statements)
0
12
0
2
Order By: Relevance
“…26 Daytime sleepiness progressively worsens in PD, confirming that it may be dependent on dopaminergic therapy 27 or an intrinsic factor of disease progression. RBD may be a useful marker to monitor progression of PD either with PSG or with a similar effect size by a 10-item self-rating questionnaire (RBD-SQ).…”
Section: Resultsmentioning
confidence: 92%
See 1 more Smart Citation
“…26 Daytime sleepiness progressively worsens in PD, confirming that it may be dependent on dopaminergic therapy 27 or an intrinsic factor of disease progression. RBD may be a useful marker to monitor progression of PD either with PSG or with a similar effect size by a 10-item self-rating questionnaire (RBD-SQ).…”
Section: Resultsmentioning
confidence: 92%
“…The effects of dopaminergic treatment on NMS vary depending up on the underlying mechanisms; i.e., a symptom influenced by dopaminergic deficit may respond positively to dopaminergic treatment (such as depression and NMS), 24 whereas a non-dopamine-responsive symptom may worsen with such treatment (such as daytime sleepiness, especially in the early titration phase; further discussion can be found in appendix e-1). 27 Therefore, we cannot remove any influence conferred by therapy on our investigational markers, but purposefully included 8 markers that are likely independent of any introduced symptomatic therapy, 34 such as MRI volumetry and blood and CSF markers.…”
Section: Resultsmentioning
confidence: 99%
“…Интерес представляют данные о существовании обратной корреляции тяжести депрессии и ДС [112]. Так, пациенты с более высоким уровнем депрессии имели меньшие значения по шкале ESS.…”
Section: дс и синдром хронической усталостиunclassified
“…Пациенты с БП могут не знать или забывать об эпизодах засыпания [114]. У больных с сопут-ствующей депрессией это может быть выражено в большей степени, поэтому результаты их тестирова-ния могут быть значительно искажены, и необходи-ма более внимательная оценка состояния больного для выявления ДС [112].…”
Section: дс и синдром хронической усталостиunclassified
“…Polysomnographic studies suggest increasing doses of dopamine prior to bedtime result in worsening sleep efficiency, increasing sleep fragmentation, and decreased REM sleep, along with poorer subjective sleep quality [24]. Not surprisingly then, levodopa use has been strongly correlated to symptoms of excessive daytime sleepiness [25, Class III].…”
Section: Pharmacologic Treatmentmentioning
confidence: 99%